Shares of Syros Pharmaceuticals SYRS plunged 86.9% on Wednesday after a late-stage study of its only pipeline candidate, ...

H.C. Wainwright has downgraded Syros Pharmaceuticals (NASDAQ:SYRS) to neutral from buy, citing Tuesday’s announcement that a ...

Syros Pharmaceuticals' Phase 3 trial of tamibarotene in higher-risk myelodysplastic syndrome did not meet primary endpoints, ...

Syros noted that SELCT-MDS-1 Phase III trial’s failure to meet its endpoint constituted a default event under its secured ...

H.C. Wainwright downgraded Syros Pharmaceuticals (SYRS) to Neutral from Buy with a price target of $1, down from $6, after ...

With the Phase III failure, Syros will discontinue the study of tamibarotene for myelodysplastic syndrome and will default on ...

Syros Pharmaceuticals’ blood cancer prospect tamibarotene has failed another study, triggering a default on a loan and wiping ...

Shares of Syros Pharmaceuticals collapsed in premarket trading Wednesday after the biopharmaceutical company's lead asset, tamibarotene, failed in a late-stage study in a rare blood cancer.

Syros Pharmaceuticals (SYRS – Research Report) received a Hold rating and price target from TD Cowen analyst Phil Nadeau yesterday. The company’s shares closed yesterday at $2.73. Nadeau covers the ...

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the ...

Find out the latest Kia Syros car price, reviews, specifications, images, mileage, videos and more. Get expert reviews on the ...

Philadelphia, Pennsylvania-- (Newsfile Corp. - November 13, 2024) - Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or ...